	US 12,220,390 B2
	Mirdametinib treatment
Uchenna H. Iloeje, Stamford, CT (US); Abraham J. Langseth, Stamford, CT (US); and Todd Webster Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics, Inc., Stamford, CT (US)
Filed on May 24, 2024, as Appl. No. 18/674,233.
Application 18/674,233 is a continuation of application No. 18/518,127, filed on Nov. 22, 2023.
Application 18/518,127 is a continuation of application No. 18/334,518, filed on Jun. 14, 2023, granted, now 11,883,375, issued on Jan. 30, 2024.
Application 18/334,518 is a continuation of application No. 18/185,148, filed on Mar. 16, 2023, granted, now 11,806,322, issued on Nov. 7, 2023.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2024/0307330 A1, Sep. 19, 2024
Int. Cl. A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/166 (2006.01); A61K 31/216 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 31/216 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)]

30 Claims

1. A method of treating a human patient 2 years to less than 12 years of age who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein an amount of mirdametinib is administered on the first day of treatment to provide an AUC_{0-12 h}less than 400 ng·h/mL.